Novos forskningsdirektør Martin Lange havde på telefonkonferencen en travl dag på kontoret, hvor næsten halvdelen (8 ud af 20 ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Medicinalselskabet Novo Nordisk overgik markedets forventninger med et overskud på 101 milliarder sidste år. Og analytikere ...

Nu svarer Novo-chefer på spørgsmål fra analytikere – følg med live her  window.addEventListener('message', (event) => { if ...

Novo Nordisk overrasker – selv skeptiker spår optur – følg med live her  window.addEventListener('message', (event) => { if ...